RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

被引:22
作者
Pan, Xiaoyan [1 ,2 ,3 ]
Shi, Jian [4 ]
Hu, Xue [1 ,3 ]
Wu, Yan [1 ]
Zeng, Liang [4 ]
Yao, Yanfeng [3 ]
Shang, Weijuan [1 ]
Liu, Kunpeng [1 ,2 ]
Gao, Ge [3 ]
Guo, Weiwei [1 ,2 ]
Peng, Yun [3 ]
Chen, Shaohong [1 ]
Gao, Xiaoxiao [3 ]
Peng, Cheng [3 ]
Rao, Juhong [1 ,2 ]
Zhao, Jiaxuan [1 ,2 ]
Gong, Cheng [4 ]
Zhou, Hui [4 ]
Lu, Yudong [4 ]
Wang, Zili [4 ]
Hu, Xiliang [4 ]
Cong, WenJuan [4 ]
Fang, Lijuan [4 ]
Yan, Yongxiang [4 ]
Zhang, Jing [4 ]
Xiong, Hui [4 ]
Yi, Jizu [4 ]
Yuan, Zhiming [1 ,2 ,3 ]
Zhou, Pengfei [4 ]
Shan, Chao [1 ,2 ,3 ]
Xiao, Gengfu [1 ,2 ,3 ]
机构
[1] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China
[2] Univ Chinese Acad Sci, Beijing, Peoples R China
[3] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Wuhan, Hubei, Peoples R China
[4] Wuhan YZY Biopharma Co Ltd, Wuhan, Hubei, Peoples R China
基金
国家重点研发计划;
关键词
SARS-COV-2;
D O I
10.1038/s41421-021-00320-y
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.
引用
收藏
页数:15
相关论文
共 49 条
  • [21] Liu Yang, 2021, bioRxiv, DOI 10.1101/2021.03.08.434499
  • [22] Neutralizing Activity of BNT162b2-Elicited Serum
    Liu, Yang
    Liu, Jianying
    Xia, Hongjie
    Zhang, Xianwen
    Fontes-Garfias, Camila R.
    Swanson, Kena A.
    Cai, Hui
    Sarkar, Ritu
    Chen, Wei
    Cutler, Mark
    Cooper, David
    Weaver, Scott C.
    Muik, Alexander
    Sahin, Ugur
    Jansen, Kathrin U.
    Xie, Xuping
    Dormitzer, Philip R.
    Shi, Pei-Yong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) : 1466 - 1468
  • [23] RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
    Liu, Zezhong
    Xu, Wei
    Xia, Shuai
    Gu, Chenjian
    Wang, Xinling
    Wang, Qian
    Zhou, Jie
    Wu, Yanling
    Cai, Xia
    Qu, Di
    Ying, Tianlei
    Xie, Youhua
    Lu, Lu
    Yuan, Zhenghong
    Jiang, Shibo
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [24] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
    Liu, Zhuoming
    VanBlargan, Laura A.
    Bloyet, Louis-Marie
    Rothlauf, Paul W.
    Chen, Rita E.
    Stumpf, Spencer
    Zhao, Haiyan
    Errico, John M.
    Theel, Elitza S.
    Liebeskind, Mariel J.
    Alford, Brynn
    Buchser, William J.
    Ellebedy, Ali H.
    Fremont, Daved H.
    Diamond, Michael S.
    Whelan, Sean P. J.
    [J]. CELL HOST & MICROBE, 2021, 29 (03) : 477 - +
  • [25] Immunoglobulin fragment F(ab′)2 against RBD potently neutralizes SARS-CoV-2 in vitro
    Pan, Xiaoyan
    Zhou, Pengfei
    Fan, Tiejiong
    Wu, Yan
    Zhang, Jing
    Shi, Xiaoyue
    Shang, Weijuan
    Fang, Lijuan
    Jiang, Xiaming
    Shi, Jian
    Sun, Yuan
    Zhao, Shaojuan
    Gong, Rui
    Chen, Ze
    Xiao, Gengfu
    [J]. ANTIVIRAL RESEARCH, 2020, 182
  • [26] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
    Planas, Delphine
    Veyer, David
    Baidaliuk, Artem
    Staropoli, Isabelle
    Guivel-Benhassine, Florence
    Rajah, Maaran Michael
    Planchais, Cyril
    Porrot, Francoise
    Robillard, Nicolas
    Puech, Julien
    Prot, Matthieu
    Gallais, Floriane
    Gantner, Pierre
    Velay, Aurelie
    Le Guen, Julien
    Kassis-Chikhani, Najiby
    Edriss, Dhiaeddine
    Belec, Laurent
    Seve, Aymeric
    Courtellemont, Laura
    Pere, Helene
    Hocqueloux, Laurent
    Fafi-Kremer, Samira
    Prazuck, Thierry
    Mouquet, Hugo
    Bruel, Timothee
    Simon-Loriere, Etienne
    Rey, Felix A.
    Schwartz, Olivier
    [J]. NATURE, 2021, 596 (7871) : 276 - +
  • [27] Spike mutation D614G alters SARS-CoV-2 fitness
    Plante, Jessica A.
    Liu, Yang
    Liu, Jianying
    Xia, Hongjie
    Johnson, Bryan A.
    Lokugamage, Kumari G.
    Zhang, Xianwen
    Muruato, Antonio E.
    Zou, Jing
    Fontes-Garfias, Camila R.
    Mirchandani, Divya
    Scharton, Dionna
    Bilello, John P.
    Ku, Zhiqiang
    An, Zhiqiang
    Kalveram, Birte
    Freiberg, Alexander N.
    Menachery, Vineet D.
    Xie, Xuping
    Plante, Kenneth S.
    Weaver, Scott C.
    Shi, Pei-Yong
    [J]. NATURE, 2021, 592 (7852) : 116 - 121
  • [28] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
    Polack, Fernando P.
    Thomas, Stephen J.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Perez, John L.
    Perez Marc, Gonzalo
    Moreira, Edson D.
    Zerbini, Cristiano
    Bailey, Ruth
    Swanson, Kena A.
    Roychoudhury, Satrajit
    Koury, Kenneth
    Li, Ping
    Kalina, Warren V.
    Cooper, David
    Frenck, Robert W., Jr.
    Hammitt, Laura L.
    Tureci, Ozlem
    Nell, Haylene
    Schaefer, Axel
    Unal, Serhat
    Tresnan, Dina B.
    Mather, Susan
    Dormitzer, Philip R.
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) : 2603 - 2615
  • [29] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
    Ramasamy, Maheshi N.
    Minassian, Angela M.
    Ewer, Katie J.
    Flaxman, Amy L.
    Folegatti, Pedro M.
    Owens, Daniel R.
    Voysey, Merryn
    Aley, Parvinder K.
    Angus, Brian
    Babbage, Gavin
    Belij-Rammerstorfer, Sandra
    Berry, Lisa
    Bibi, Sagida
    Bittaye, Mustapha
    Cathie, Katrina
    Chappell, Harry
    Charlton, Sue
    Cicconi, Paola
    Clutterbuck, Elizabeth A.
    Colin-Jones, Rachel
    Dold, Christina
    Emary, Katherine R. W.
    Fedosyuk, Sofiya
    Fuskova, Michelle
    Gbesemete, Diane
    Green, Catherine
    Hallis, Bassam
    Hou, Mimi M.
    Jenkin, Daniel
    Joe, Carina C. D.
    Kelly, Elizabeth J.
    Kerridge, Simon
    Lawrie, Alison M.
    Lelliott, Alice
    Lwin, May N.
    Makinson, Rebecca
    Marchevsky, Natalie G.
    Mujadidi, Yama
    Munro, Alasdair P. S.
    Pacurar, Mihaela
    Plested, Emma
    Rand, Jade
    Rawlinson, Thomas
    Rhead, Sarah
    Robinson, Hannah
    Ritchie, Adam J.
    Ross-Russell, Amy L.
    Saich, Stephen
    Singh, Nisha
    Smith, Catherine C.
    [J]. LANCET, 2020, 396 (10267) : 1979 - 1993
  • [30] Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
    Richmond, Peter
    Hatchuel, Lara
    Dong, Min
    Ma, Brenda
    Hu, Branda
    Smolenov, Igor
    Li, Ping
    Liang, Peng
    Han, Htay Htay
    Liang, Joshua
    Clemens, Ralf
    [J]. LANCET, 2021, 397 (10275) : 682 - 694